Insulin-like Growth Factors Market Share & Trends Analysis Report, By Type (Mechano Growth Factor, Somatomedin C, IGF 1), By End-user (Hospitals, Medical Centers), By Region, and Segment Forecasts, 2023-2031

Insulin-like Growth Factors Market Size is valued at USD 275.1 Mn in 2023 and is predicted to reach USD 406.1 Mn by the year 2031 at an 5.13% CAGR during the forecast period for 2024-2031.

Insulin-like growth factors (IGFs) are proteins that resemble insulin in structure and share some of its effects. Their primary function, however, is to stimulate cell growth and development throughout the body, forming part of a complex system known as the IGF axis. There are two main types of IGFs: IGF-1 and IGF-2. IGF-1 is a hormone that mediates the effects of growth hormone (GH) in the body. Together, IGF-1 and GH promote the normal growth of bones and tissues. Unlike GH levels, which fluctuate throughout the day based on diet and activity levels, IGF-1 levels remain relatively stable. Therefore, an IGF-1 test is a valuable tool for determining if the body is producing a normal amount of GH. IGFs play a significant role in muscle growth and repair. They enhance protein synthesis and muscle cell proliferation, making them important for muscle recovery and strength. IGFs are crucial for normal growth and development, particularly during childhood and adolescence. They stimulate the growth of bones and tissues, ensuring proper physical development.

IGF levels vary with age. They are typically highest during childhood and adolescence, supporting rapid growth and development. Levels decline with age, contributing to the decreased regenerative capacity seen in older adults. Regular exercise can enhance IGF-1 levels, particularly resistance training and high-intensity interval training (HIIT). Physical activity stimulates muscle growth and repair, processes in which IGFs play a critical role.

Competitive Landscape

Some of the Major Key Players in the Insulin-like Growth Factors Market are

• Boehringer Ingelheim International GmbH
• Genervon Biopharmaceuticals LLC
• Ascendis Pharma
• Regulaxis SAS
• MedImmune, LLC
• Other Prominent Players

Market Segmentation:

The is segmented based on by type, by end-user, and by region. Based on the by type, the segment is divided into mechano growth factor, somatomedin C, and IGF 1. Based on the end user, the market segment is divided into hospitals and medical centers.

The IGF-1 Segment is Expected to have growth rate during the forecast period

Based on the type, the market segment is divided into the mechano growth factor, somatomedin C, and IGF 1. Among these, the IGF-1 segment is expected to have growth rate during the forecast period. IGF-1 has a clearer and more established role in the body compared to IGF-2. IGF-1 is known to be crucial for growth and development throughout life, impacting bones, muscles, and organs. IGF-1 has a wide range of clinical applications, making it a highly sought-after therapeutic agent. It is used in treating growth hormone deficiencies, chronic conditions like diabetes, muscle wasting diseases, and certain forms of dwarfism. Its broad therapeutic potential drives significant demand in the market.

The Hospitals Segment Dominate the Market

The end-user segment is categorized into hospitals and medical centers. Among these, the hospital segment dominates the market. Hospitals are primary sites for administering IGF-based therapies. These institutions handle the diagnosis and treatment of growth hormone deficiencies, chronic conditions, and other medical issues that require IGF therapies. Their role in providing specialized medical care makes them crucial players in the IGF market. Hospitals often serve as hubs for clinical research and trials. These institutions conduct studies on IGF-1's efficacy and safety for various conditions, contributing to advancements in IGF-based treatments and boosting market growth.

North America is the Fastest-Growing Region During the Forecast Period.

North America is expected to expand at the highest rate.  The region faces a significant burden of chronic diseases like diabetes, cancer, and chronic kidney disease. These conditions are often associated with impaired growth factor signaling, and IGFs are being explored as potential therapeutic agents. The regulatory environment in North America might be more streamlined compared to some other regions, potentially facilitating faster approval of IGF-based therapies.  North America has a high level of healthcare spending compared to other regions. This allows for greater investment in research, development, and adoption of new technologies and treatments, including IGF-based therapies.

Recent Developments:

• In Aug 2021, Ascendis Pharma A/S, a biopharmaceutical company, confirmed that the US Food and Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of pediatric patients aged one year and up who weigh at least 11.5 kg (25.4 lb) and have growth failure caused by insufficient secretion of endogenous growth hormone (GH). The company's cutting-edge TransCon technologies might lead to the development of new medicines that have a significant impact on patients' lives.

Insulin-like Growth Factors Market Report Scope

Segmentation of Insulin-like Growth Factors Market

Global Insulin-like Growth Factors Market, By Type

• Mechano Growth Factor
• Somatomedin C
• IGF 1

Global Insulin-like Growth Factors Market – By End-user

• Hospitals
• Medical Centers

Global Insulin-like Growth Factors Market – By Region

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of the Middle East and Africa